IDH1 mutation may not be prognostically favorable in glioblastoma when controlled for tumor location: A case-control study

Journal of Clinical Neuroscience

Volumn 34, Issue , 2016, Pages 117-120

  Paldor, Iddo ^a   Drummond, Katharine J ^a,b   Kaye, Andrew H ^b  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Case control; Glioblastoma multiforme; IDH 1 mutation; Tumor location

Indexed keywords

ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE;

ADULT; AGE DISTRIBUTION; ARTICLE; CANCER PROGNOSIS; CASE CONTROL STUDY; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; HUMAN; MALE; MIDDLE AGED; MUTATIONAL ANALYSIS; NEUROSURGERY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEX DIFFERENCE; TUMOR DIFFERENTIATION; TUMOR LOCALIZATION; TUMOR VOLUME; WILD TYPE; BRAIN NEOPLASMS; GENETICS; MUTATION; PATHOLOGY; PROGNOSIS; SURVIVAL ANALYSIS;

BRAIN NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GLIOBLASTOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 84994351184     PISSN: 09675868     EISSN: 15322653     Source Type: Journal    
DOI: 10.1016/j.jocn.2016.05.016     Document Type: Article

References (30)

1. [1] Ostrom, Q.T., Gittleman, H., Farah, P., et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006–2010. Neuro Oncol 15 (2013), ii1–ii56.
2. [2] Stupp, R., Mason, W.P., van den Bent, M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 (2005), 987–996.
3. [3] Stummer, W., Pichlmeier, U., Meinel, T., et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7 (2006), 392–401.
4. [4] Brem, H., Piantadosi, S., Burger, P.C., et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 345 (1995), 1008–1012.
5. [5] Paldor, I., Drummond, K.J., Awad, M., et al. Is a wake-up call in order? Review of the evidence for awake craniotomy. J Clin Neurosci 23 (2016), 1–7.
6. [6] Raizer, J.J., Grimm, S., Chamberlain, M.C., et al. A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. Cancer 116 (2010), 5297–5305.
7. [7] Siegal, T., Charbit, H., Paldor, I., et al. Dynamics of circulating hypoxia-mediated miRNAs and tumor response in patients with high-grade glioma treated with bevacizumab. J Neurosurg, 2016, 1–8 [Epub ahead of print].
8. [8] Thuy, M.N., Kam, J.K., Lee, G.C., et al. A novel literature-based approach to identify genetic and molecular predictors of survival in glioblastoma multiforme: analysis of 14,678 patients using systematic review and meta-analytical tools. J Clin Neurosci 22 (2015), 785–799.
9. [9] Morokoff, A., Ng, W., Gogos, A., et al. Molecular subtypes, stem cells and heterogeneity: implications for personalised therapy in glioma. J Clin Neurosci 22 (2015), 1219–1226.
10. [10] Areeb, Z., Stylli, S.S., Koldej, R., et al. MicroRNA as potential biomarkers in glioblastoma. J Neurooncol 125 (2015), 237–248.
11. [11] Bleeker, F.E., Lamba, S., Leenstra, S., et al. IDH1 mutations at residue p. R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat 30 (2009), 7–11.
12. [12] Parsons, D.W., Jones, S., Zhang, X., et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321 (2008), 1807–1812.
13. [13] Yan, H., Parsons, D.W., Jin, G., et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 360 (2009), 765–773.
14. [14] Nobusawa, S., Watanabe, T., Kleihues, P., et al. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 15 (2009), 6002–6007.
15. [15] Louis, D.N., Ohgaki, H., Wiestler, O.D., et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114 (2007), 97–109.
16. [16] Kalkan, R., Atli, E.I., Ozdemir, M., et al. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme. Gene 554 (2015), 81–86.
17. [17] Liu, A., Hou, C., Chen, H., et al. Genetics and epigenetics of glioblastoma: applications and overall incidence of IDH1 mutation. Front Oncol, 6, 2016, 16.
18. [18] Paldor, I., Pearce, F.C., Drummond, K.J., et al. Frontal glioblastoma multiforme may be biologically distinct from non-frontal and multilobar tumors. J Clin Neurosci 34 (2016), 128–132.
19. [19] Denicolai, E., Tabouret, E., Colin, C., et al. Molecular heterogeneity of glioblastomas; does location matter?. Oncotarget 7 (2016), 902–913.
20. [20] Qi, S., Yu, L., Li, H., et al. Isocitrate dehydrogenase mutation is associated with tumor location and magnetic resonance imaging characteristics in astrocytic neoplasms. Oncol Lett 7 (2014), 1895–1902.
21. [21] Sun, Z.L., Chan, A.K., Chen, L.C., et al. TERT promoter mutated WHO grades II and III gliomas are located preferentially in the frontal lobe and avoid the midline. Int J Clin Exp Pathol 8 (2015), 11485–11494.
22. [22] Young, G.S., Macklin, E.A., Setayesh, K., et al. Longitudinal MRI evidence for decreased survival among periventricular glioblastoma. J Neurooncol 104 (2011), 261–269.
23. [23] Chaichana, K., Parker, S., Olivi, A., et al. A proposed classification system that projects outcomes based on preoperative variables for adult patients with glioblastoma multiforme. J Neurosurg 112 (2010), 997–1004.
24. [24] Dziurzynski, K., Blas-Boria, D., Suki, D., et al. Butterfly glioblastomas: a retrospective review and qualitative assessment of outcomes. J Neurooncol 109 (2012), 555–563.
25. [25] Delgado-Lopez, P.D., Corrales-Garcia, E.M., Survival in glioblastoma: a review on the impact of treatment modalities. Clin Transl Oncol, 2016 [Epub ahead of print].
26. [26] Bleeker, F.E., Atai, N.A., Lamba, S., et al. The prognostic IDH1(R132) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. Acta Neuropathol 119 (2010), 487–494.
27. [27] Chen, J.R., Yao, Y., Xu, H.Z., et al. Isocitrate dehydrogenase (IDH)1/2 mutations as prognostic markers in patients with glioblastomas. Medicine (Baltimore), 95, 2016, e2583.
28. [28] Takano, S., Kato, Y., Yamamoto, T., et al. Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors. J Neurooncol 108 (2012), 361–373.
29. [29] Gorlia, T., Delattre, J.Y., Brandes, A.A., et al. New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. Eur J Cancer 49 (2013), 3477–3485.
30. [30] de Quintana-Schmidt, C., Alvarez-Holzapfel, M.J., Nomdedeu-Guinot, J., et al. Isocitrate dehydrogenase type I mutation as a prognostic factor in glioblastoma and a literature review. Neurocirugia (Astur) 26 (2015), 276–283.